ZA943104B - HIV protease inhibitors useful for the treatment of aids - Google Patents

HIV protease inhibitors useful for the treatment of aids

Info

Publication number
ZA943104B
ZA943104B ZA943104A ZA943104A ZA943104B ZA 943104 B ZA943104 B ZA 943104B ZA 943104 A ZA943104 A ZA 943104A ZA 943104 A ZA943104 A ZA 943104A ZA 943104 B ZA943104 B ZA 943104B
Authority
ZA
South Africa
Prior art keywords
aids
treatment
protease inhibitors
hiv protease
inhibitors useful
Prior art date
Application number
ZA943104A
Other languages
English (en)
Inventor
Joseph P Vacca
Bruce D Dorsey
James P Guare
M Katharine Holloway
Randall W Hungate
Rhonda B Levin
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of ZA943104B publication Critical patent/ZA943104B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
ZA943104A 1993-05-07 1994-05-05 HIV protease inhibitors useful for the treatment of aids ZA943104B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/059,038 US5413999A (en) 1991-11-08 1993-05-07 HIV protease inhibitors useful for the treatment of AIDS

Publications (1)

Publication Number Publication Date
ZA943104B true ZA943104B (en) 1995-11-06

Family

ID=22020419

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA943104A ZA943104B (en) 1993-05-07 1994-05-05 HIV protease inhibitors useful for the treatment of aids

Country Status (20)

Country Link
US (3) US5413999A (OSRAM)
EP (1) EP0696277A1 (OSRAM)
JP (1) JPH08509980A (OSRAM)
CN (2) CN1126469A (OSRAM)
AU (1) AU676563B2 (OSRAM)
BG (1) BG100114A (OSRAM)
BR (1) BR9406576A (OSRAM)
CA (1) CA2161334A1 (OSRAM)
CZ (1) CZ290095A3 (OSRAM)
FI (1) FI955315A7 (OSRAM)
HR (1) HRP940286A2 (OSRAM)
HU (1) HUT73135A (OSRAM)
IL (1) IL109503A0 (OSRAM)
MX (1) MX9403380A (OSRAM)
NO (1) NO954427L (OSRAM)
PL (1) PL311635A1 (OSRAM)
SK (1) SK136395A3 (OSRAM)
TW (1) TW256830B (OSRAM)
WO (1) WO1994026717A1 (OSRAM)
ZA (1) ZA943104B (OSRAM)

Families Citing this family (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413999A (en) * 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5717097A (en) * 1991-11-08 1998-02-10 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
CA2140929C (en) 1992-08-25 2006-09-12 Michael L. Vazquez Hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
IL111584A0 (en) * 1993-11-18 1995-01-24 Merck & Co Inc Prodrugs of an inhibitor of hiv protease and pharmaceutical compositions containing them
WO1995016688A1 (en) * 1993-12-15 1995-06-22 Merck & Co., Inc. Hiv protease inhibitors
TW472047B (en) * 1994-02-04 2002-01-11 Merck & Co Inc Process for making HIV protease inhibitors
DE59508739D1 (de) * 1994-04-20 2000-10-26 Lonza Ag Verfahren zur herstellung von 2-piperazincarbonsäurederivaten
US5489685A (en) * 1994-05-12 1996-02-06 Merck & Co., Ltd. Method of synthesizing furo[2,3-b]pyridine carboxylic acid esters
UA49803C2 (uk) * 1994-06-03 2002-10-15 Дж.Д. Сьорль Енд Ко Спосіб лікування ретровірусних інфекцій
US20030207813A1 (en) * 1996-12-09 2003-11-06 G.D. Searle Retroviral protease inhibitor combinations
US5612217A (en) * 1994-10-25 1997-03-18 Merck & Co., Inc. Streptomyces sp. MA 7074 (ATCC 55605) used for microbial synthesis of HIV protease inhibitors
DE69501705T2 (de) * 1994-11-04 1998-06-25 Yamakawa Chemical Ind Verfahren zur Herstellung von optisch aktiven Piperazinderivaten und Zwischenprodukten für ihre Herstellung
PT805803E (pt) * 1995-01-23 2003-03-31 Lonza Ag Processo para a producao de amidas de acido 1,4,5,6-tetra-hidropirazino-2-carboxilico
US6689761B1 (en) * 1995-02-01 2004-02-10 Merck & Co., Inc. Combination therapy for HIV infection
US5618937A (en) * 1995-03-15 1997-04-08 Merck & Co., Inc. Process to make HIV protease inhibitor from (2S)-4-picolyl-2-piperazine-t-butylcarboxamide
US5605819A (en) * 1995-05-19 1997-02-25 Merck & Co., Inc. Quantitative conversion of indene to (1S,2R) indene oxide and (1S,2R)-indandiol by combination of haloperoxidase bioconversion and chemical steps
JP3665976B2 (ja) * 1995-06-29 2005-06-29 東レ・ファインケミカル株式会社 光学分割剤およびそれを用いた光学活性Ｎ−ｔｅｒｔ−ブチル−２−ピペラジンカルボキシアミドの製造法
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
GB2307683A (en) * 1995-10-31 1997-06-04 Merck & Co Inc HIV protease inhibitors useful for the treatment of AIDS
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
CA2279669A1 (en) * 1995-12-15 1997-06-16 Enzo Therapeutics, Inc. Property effecting and/or property exhibiting constructs for the expression of non-native nucleic acid processing components for therapeutic and diagnostic uses
US5883252A (en) * 1996-01-26 1999-03-16 Vertex Pharmaceuticals Incorporated Aspartyl protease inhibitors
EP0912170A4 (en) * 1996-05-02 2003-04-09 Merck & Co Inc HIV PROTEASE INHIBITORS FOR TREATING AIDS
US5846978A (en) * 1996-05-02 1998-12-08 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5811462A (en) * 1996-05-02 1998-09-22 Merck & Co., Inc. HIV Protease inhibitors useful for the treatment of AIDS
US5747540A (en) * 1996-10-21 1998-05-05 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5783709A (en) * 1996-10-31 1998-07-21 Merck & Co., Inc. Stereoselective process for making substituted amino acid derivatives
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
US6232333B1 (en) 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
US6645961B1 (en) * 1997-03-07 2003-11-11 Merck & Co., Inc. Dry granulation formulation for an HIV protease inhibitor
CN1103221C (zh) 1997-04-15 2003-03-19 领先病毒研究公司 治疗人类免疫缺陷性病毒感染的药物
US5981759A (en) * 1997-06-20 1999-11-09 Merck & Co., Inc. Process for indinavir intermediate
HRP980443A2 (en) * 1997-08-18 1999-10-31 Carl P. Decicco Novel inhibitors of aggrecanase and matrix metalloproteinases for the treatment of arthritis
US6180634B1 (en) 1997-11-13 2001-01-30 Merck & Co., Inc. Combination therapy for the treatment of AIDS
US6143742A (en) * 1997-12-11 2000-11-07 Fuisz Technologies Ltd Treatment for necrotizing infections
GB2336841A (en) 1998-04-28 1999-11-03 Merck & Co Inc Preparation of cis-(is,2r)-indanediol by the microbial reduction of 1,2-indanedione
US7045519B2 (en) * 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
CN1312807A (zh) 1998-06-19 2001-09-12 希龙公司 糖元合成酶激酶3的抑制剂
BR9911457A (pt) * 1998-06-24 2001-12-11 Univ Emory Uso de 3'-azida-2', 3'-dideoxiuridina em combinaçãocom drogas anti-hiv adicionais para a manufaturade um medicamento para o tratamento de hiv
EP1095022A1 (en) * 1998-07-08 2001-05-02 G.D. Searle & Co. Retroviral protease inhibitors
GB2341385A (en) 1998-09-14 2000-03-15 Merck & Co Inc Recovery of iodide from chemical process waste water
US7115584B2 (en) * 1999-01-22 2006-10-03 Emory University HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
US7635690B2 (en) * 1999-01-22 2009-12-22 Emory University HIV-1 mutations selected for by β-2′,3′-didehydro-2′,3′-dideoxy-5-fluorocytidine
AU2753700A (en) * 1999-02-03 2000-08-25 Julianna Lisziewicz Use of hydroxyurea and a reverse transcriptase inhibitor to induce autovaccination by autologous hiv
PT1733725E (pt) * 1999-06-04 2009-06-30 Abbott Lab Formulações farmacêuticas compreendendo pelo menos um composto inibidor da protease de hiv
DE60045005D1 (de) * 1999-06-28 2010-11-04 Oklahoma Med Res Found Inhibitoren des memapsin 2 und ihre verwendung
WO2001005230A1 (en) * 1999-07-20 2001-01-25 Merck & Co., Inc. Alpha-hydroxy-gamma-[[(carbocyclic-or heterocyclic-substituted)amino]carbonyl]alkanamide derivatives and uses thereof
US6589962B1 (en) 1999-07-20 2003-07-08 Merck & Co., Inc. Alpha-hydroxy-gamma-[[(carbocyclic-or heterocyclic-substituted)amino]carbonyl]alkanamide derivatives and uses thereof
NL1012825C2 (nl) * 1999-08-13 2001-02-23 Faculteit Geneeskunde Universi Farmaceuticum voor de behandeling van virale infecties in het bijzonder van het humane immunodeficiency virus (HIV).
WO2001038332A1 (en) * 1999-11-24 2001-05-31 Merck & Co., Inc. Gamma-hydroxy-2-(fluoroalkylaminocarbonyl)-1-piperazinepentanamides as hiv protease inhibitors
NZ519724A (en) * 2000-01-19 2004-07-30 Abbott Lab Chad 0377 Ap6D 2 A combination solubilised HIV protease inhibiting compound, a medium and or long clain fatty acid and an alcohol that has improved solubility properties
US6476034B2 (en) * 2000-02-22 2002-11-05 Bristol-Myers Squibb Company Antiviral azaindole derivatives
WO2001082964A1 (en) * 2000-04-28 2001-11-08 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Improved immunogenicity using a combination of dna and vaccinia virus vector vaccines
AU2001259817A1 (en) 2000-05-04 2001-11-12 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The National Institutes Of Health Methods of and compounds for inhibiting calpains
US6384244B2 (en) 2000-05-18 2002-05-07 Merck & Co., Inc. Process for preparing cis- aminochromanols
US6482952B2 (en) 2000-06-20 2002-11-19 Merck & Co., Inc. Process for preparing acetonides
US6573262B2 (en) 2000-07-10 2003-06-03 Bristol-Myers Sqibb Company Composition and antiviral activity of substituted indoleoxoacetic piperazine derivatives
US6531617B2 (en) 2000-10-24 2003-03-11 Merck & Co., Inc. Process for preparing hydroxychomanones and cis-aminochromanols
WO2002057287A2 (en) 2001-01-22 2002-07-25 Merck & Co., Inc. Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
US20030207910A1 (en) 2001-02-02 2003-11-06 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7202092B2 (en) * 2001-07-13 2007-04-10 Roche Diagnostics Operations, Inc. Indinavir derivatives useful in immunoassay
US20030191121A1 (en) * 2001-08-09 2003-10-09 Miller Ross A. Piperazine carboxamide intermediates of HIV protease inhibitors and processes for their preparation
US7279487B2 (en) * 2002-01-17 2007-10-09 Merck & Co., Inc. Hydroxynaphthyridinone carboxamides useful as HIV integrase inhibitors
US20040067216A1 (en) * 2002-02-22 2004-04-08 Karki Shyam B. Hiv protease inhibitors supported on cation exchange resins for oral administration
EP2316469A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
WO2004041997A2 (en) * 2002-05-01 2004-05-21 National Institutes Of Health Immunotherapy regimens in hiv-infected patients
KR101128370B1 (ko) 2002-05-16 2012-04-23 티보텍 파마슈티컬즈 Ｈｉｖ 프로테아제 저해제의 유사다형체
AU2003276047A1 (en) * 2002-06-17 2003-12-31 Sunesis Pharmaceuticals, Inc. Aspartyl protease inhibitors
US7115652B2 (en) * 2002-06-17 2006-10-03 Sunesis Pharmaceuticals, Inc. Aspartyl protease inhibitors
US8876532B2 (en) 2002-07-31 2014-11-04 Dentsply International Inc. Bone repair putty
US7199240B2 (en) * 2002-12-11 2007-04-03 Merck & Co., Inc. Reductive alkylation of saturated cyclic amines
WO2005123087A2 (en) 2004-06-15 2005-12-29 Merck & Co., Inc. C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase
US7772271B2 (en) * 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7781478B2 (en) * 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
JP2008506702A (ja) * 2004-07-14 2008-03-06 ピーティーシー セラピューティクス，インコーポレーテッド Ｃ型肝炎を治療するための方法
US7868037B2 (en) * 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7645881B2 (en) * 2004-07-22 2010-01-12 Ptc Therapeutics, Inc. Methods for treating hepatitis C
KR101233824B1 (ko) 2004-07-27 2013-02-18 길리애드 사이언시즈, 인코포레이티드 Ｈｉｖ 억제제 화합물인 포스포네이트 유사체
US20060100209A1 (en) * 2004-11-09 2006-05-11 Chong-Hui Gu Formulations of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
US20060100432A1 (en) * 2004-11-09 2006-05-11 Matiskella John D Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
UA87884C2 (uk) * 2004-12-03 2009-08-25 Мерк Энд Ко., Инк. Безводна кристалічна калієва сіль інгібітора віл-інтегрази
US7598380B2 (en) * 2005-08-03 2009-10-06 Bristol-Myers Squibb Company Method of preparation of azaindole derivatives
JP2009505979A (ja) * 2005-08-10 2009-02-12 オクラホマ メディカル リサーチ ファンデーション アルツハイマー病の治療に使用するためのトランケート型メマプシン２
GB2443591B (en) * 2005-09-07 2010-04-28 Secr Defence Adjuvanted vaccine
GB0519871D0 (en) * 2005-09-30 2005-11-09 Secr Defence Immunogenic agents
US7851476B2 (en) * 2005-12-14 2010-12-14 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine
US7807671B2 (en) * 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
US8323664B2 (en) * 2006-07-25 2012-12-04 The Secretary Of State For Defence Live vaccine strains of Francisella
EP2124555B1 (en) 2007-01-05 2015-07-08 Merck Sharp & Dohme Corp. Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection
EP2522367B1 (en) 2007-03-12 2016-01-20 Nektar Therapeutics Oligomer-protease inhibitor conjugates
GB0709791D0 (en) * 2007-05-22 2007-06-27 Angeletti P Ist Richerche Bio Antiviral agents
CN101743004A (zh) * 2007-06-29 2010-06-16 吉里德科学公司 治疗用组合物及其用途
AP2965A (en) * 2007-06-29 2014-09-30 Gilead Sciences Inc Therapeutic compositions and the use thereof
GB0718575D0 (en) * 2007-09-24 2007-10-31 Angeletti P Ist Richerche Bio Nucleoside derivatives as inhibitors of viral polymerases
EP2203420A1 (en) * 2007-09-25 2010-07-07 Merck Sharp & Dohme Corp. Hiv protease inhibitors
GB0720503D0 (en) * 2007-10-22 2007-11-28 Angeletti P Ist Richerche Bio New compound
US9095620B2 (en) * 2008-03-12 2015-08-04 Nektar Therapeutics Reagents
EA021377B9 (ru) 2008-12-09 2015-09-30 Джилид Сайэнс, Инк. Модуляторы толл-подобных рецепторов
GB0900455D0 (en) 2009-01-13 2009-02-11 Secr Defence Vaccine
GB0901411D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
GB0901423D0 (en) 2009-01-29 2009-03-11 Secr Defence Treatment
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
WO2010138338A1 (en) 2009-05-27 2010-12-02 Merck Sharp & Dohme Corp. Hiv protease inhibitors
EP2440249A2 (en) 2009-06-12 2012-04-18 Nektar Therapeutics Covalent conjugates comprising a protease inhibitor, a water-soluble, non-peptidic oligomer and a lipophilic moiety
DE102010004957A1 (de) 2010-01-14 2011-07-21 Universitätsklinikum Jena, 07743 Biologisch wirksame Moleküle zur Beeinflussung von Virus-, Bakterien-, Parasiten-infizierten Zellen und/oder Tumorzellen und Verfahren zu deren Anwendung
US20110223131A1 (en) 2010-02-24 2011-09-15 Gilead Sciences, Inc. Antiviral compounds
US20130052221A1 (en) 2010-02-26 2013-02-28 The Govt. of the U.S, as represented by The Sec. of The Dept. of Health and Human Services Dna-protein vaccination protocols
EP2576586B1 (en) 2010-06-04 2015-08-12 Bristol-Myers Squibb Company C-28 amides of modified c-3 betulinic acid derivatives as hiv maturation inhibitors
MX2012013703A (es) 2010-06-04 2012-12-17 Bristol Myers Squibb Co Derivados de acido c-3-betulinico modificados como inhibidores de la maduracion del virus de inmunodeficiencia humana (vih).
US8450361B2 (en) 2010-08-06 2013-05-28 Bristol-Myers Squibb Company Substituted indole and azaindole oxoacetyl piperazinamide derivatives
US9079834B2 (en) 2010-10-28 2015-07-14 Merck Canada Inc. HIV protease inhibitors
US8912195B2 (en) 2010-12-02 2014-12-16 Bristol-Myers Squibb Company Alkyl amides as HIV attachment inhibitors
PT2670765T (pt) 2011-01-31 2018-01-08 Viiv Healthcare Uk No 4 Ltd Triterpenoides modificados em c-17 e c-3 com atividade inibidora da maturação do vih
ES2552512T3 (es) 2011-01-31 2015-11-30 Bristol-Myers Squibb Company Aminas C-28 de derivados de ácido betulínico modificado en C-3 como inhibidores de la maduracion del virus de inmunodeficiencia humana
ES2636312T3 (es) 2011-04-12 2017-10-05 VIIV Healthcare UK (No.5) Limited Derivados de tioamida, amidoxima y amidrazona como inhibidores de la fijación del VIH
WO2013033061A1 (en) 2011-08-29 2013-03-07 Bristol-Myers Squibb Company Fused bicyclic diamine derivatives as hiv attachment inhibitors
EP2751118B1 (en) 2011-08-29 2016-10-12 Bristol-Myers Squibb Company Spiro bicyclic diamine derivatives as hiv attachment inhibitors
JP6100786B2 (ja) 2011-09-21 2017-03-22 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ウイルス活性を有する新規ベツリン酸誘導体
EP2771332B1 (en) 2011-10-26 2016-06-29 Merck Canada Inc. Thiophen and thiazol sulfonamid derivatives as HIV protease inhibitors for the treatment of AIDS
US8906889B2 (en) 2012-02-15 2014-12-09 Bristol-Myers Squibb Company C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity
US9193725B2 (en) 2012-03-14 2015-11-24 Bristol-Meyers Squibb Company Cyclic hydrazine derivatives as HIV attachment inhibitors
US8889854B2 (en) 2012-05-07 2014-11-18 Bristol-Myers Squibb Company C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity
US9655888B2 (en) 2012-08-09 2017-05-23 VIIV Healthcare UK (No.5) Limited Tricyclic alkene derivatives as HIV attachment inhibitors
WO2014025854A1 (en) 2012-08-09 2014-02-13 Bristol-Myers Squibb Company Piperidine amide derivatives as hiv attachment inhibitors
RU2015113091A (ru) 2012-09-11 2016-11-10 Мерк Шарп И Доум Корп. Ингибиторы протеазы вич
CN105121454A (zh) 2013-02-06 2015-12-02 百时美施贵宝公司 具有hiv成熟抑制活性的c-19经修饰的三萜类化合物
MX2015010354A (es) 2013-02-25 2015-10-09 Squibb Bristol Myers Co Derivados de acido betulinico modificados con aquilo c-3 y alquenilo utiles en el tratamiento de virus de inmunodeficiencia humana (vih).
WO2015013835A1 (en) 2013-07-31 2015-02-05 Merck Sharp & Dohme Corp. Piperazine derivatives as hiv protease inhibitors
US9834526B2 (en) 2013-12-19 2017-12-05 Merck Sharp & Dohme Corp. HIV protease inhibitors
US9737545B2 (en) 2013-12-19 2017-08-22 Merck Sharp & Dohme Corp. HIV protease inhibitors
DE102014202609B4 (de) 2014-02-13 2020-06-04 tooz technologies GmbH Aminkatalysierte Thiolhärtung von Epoxidharzen
EP3113780B1 (en) 2014-03-06 2019-08-14 Merck Sharp & Dohme Corp. Hiv protease inhibitors
EP3116862B1 (en) 2014-03-10 2019-04-17 Merck Sharp & Dohme Corp. Piperazine derivatives as hiv protease inhibitors
NZ724644A (en) 2014-04-11 2023-07-28 Viiv Healthcare Uk No 4 Ltd Triterpenoids with hiv maturation inhibitory activity, substituted in position 3 by a non-aromatic ring carrying a haloalkyl substituent
US9920090B2 (en) 2014-06-19 2018-03-20 VIIV Healthcare UK (No.5) Limited Betulinic acid derivatives with HIV maturation inhibitory activity
WO2016001907A1 (en) 2014-07-02 2016-01-07 Prendergast Patrick T Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
CN113577081A (zh) 2014-07-11 2021-11-02 吉利德科学公司 用于治疗hiv的toll样受体调节剂
US9738664B2 (en) 2014-10-29 2017-08-22 Wisconsin Alumni Research Foundation Boronic acid inhibitors of HIV protease
US9969767B2 (en) 2014-11-14 2018-05-15 VIIV Healthcare UK (No.5) Limited Oxolupene derivatives
RU2017118576A (ru) 2014-11-14 2018-12-14 ВАЙВ ХЕЛТКЕР ЮКей (N5) ЛИМИТЕД C-17-арил-замещённые аналоги бетулиновой кислоты
AU2016248235A1 (en) 2015-04-14 2017-10-19 Viiv Healthcare Uk (No 4) Limited Crystalline forms of modified triterpenoid hydrochloride salts with HIV maturation inhibitor activity
US20180346520A1 (en) 2015-05-13 2018-12-06 The United States Of America As Represented By The Secretary Of The Department Of Health And Methods and compositions for inducing an immune response using conserved element constructs
AU2016322763A1 (en) 2015-09-15 2018-04-19 Gilead Sciences, Inc. Modulators of toll-like recptors for the treatment of HIV
AR107512A1 (es) 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
US10239847B1 (en) 2016-03-03 2019-03-26 Cellactin Method for 2-oxothiazolidine-4-carboxylic acid for cellular glutathione
CN108324716A (zh) * 2018-04-18 2018-07-27 日照市普达医药科技有限公司 一种含有茚地那韦的抗hiv药物及制备方法
WO2024011033A1 (en) 2022-07-07 2024-01-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Immunogens and methods for inducing an immune response

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4198509A (en) * 1978-10-30 1980-04-15 E. R. Squibb & Sons, Inc. Mercaptoacylpiperazine carboxylic acid compounds
DE3134933A1 (de) * 1981-09-03 1983-03-31 Hoechst Ag, 6230 Frankfurt "harnstoffderivate, verfahren zu ihrer herstellung und diese enthaltende medikamente sowie deren verwendung"
US4661473A (en) * 1984-03-27 1987-04-28 Merck & Co., Inc. Renin inhibitors containing peptide isosteres
EP0486478A3 (en) * 1984-08-06 1992-08-12 The Upjohn Company Renin-inhibiting peptides
CA1290097C (en) * 1985-07-24 1991-10-01 Merck & Co., Inc. Peptide enzyme inhibitors
CA1309555C (en) * 1986-02-27 1992-10-27 Suvit Thaisrivongs Inhibiting peptides having a dihydroxyethylene isostere transitionstate insert
IL89900A0 (en) * 1988-04-12 1989-12-15 Merck & Co Inc Hiv protease inhibitors useful for the treatment of aids and pharmaceutical compositions containing them
IL90218A0 (en) * 1988-05-13 1989-12-15 Abbott Lab Retroviral protease inhibitors
IL91307A0 (en) * 1988-08-24 1990-03-19 Merck & Co Inc Hiv protease inhibitors and pharmaceutical compositions for the treatment of aids containing them
EP0357332A3 (en) * 1988-08-24 1991-07-31 Merck & Co. Inc. Renin inhibitors useful for the treatment of aids by inhibition of hiv protease
CA2010531A1 (en) * 1989-03-06 1990-09-06 Werner Neidhart Amino acid derivatives
US5063208A (en) * 1989-07-26 1991-11-05 Abbott Laboratories Peptidyl aminodiol renin inhibitors
IE902446A1 (en) * 1989-07-26 1991-02-13 Abbott Lab Peptidyl aminodiol renin inhibitors
IE902944A1 (en) * 1989-09-05 1991-03-13 Abbott Lab Peptidyl difluorodiol renin inhibitors
GB8927915D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Novel alcohols
GB8927913D0 (en) * 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
CA2032259A1 (en) * 1989-12-18 1991-06-19 Wayne J. Thompson Hiv protease inhibitors useful for the treatment of aids
CA2055685A1 (en) * 1990-11-19 1992-05-20 Samuel L. Graham Hiv protease inhibitors having polyether substituents
IE913840A1 (en) * 1990-11-20 1992-05-20 Abbott Lab Retroviral protease inhibiting compounds
EP0492136A3 (en) * 1990-12-20 1993-05-26 American Cyanamid Company Retroviral protease inhibitors derived from 3-chloro-2-chloromethyl-1-propene
AU1531092A (en) * 1991-02-22 1992-09-15 Du Pont Merck Pharmaceutical Company, The Substituted alpha-aminoaldehydes and derivatives
US5430041A (en) * 1991-05-10 1995-07-04 Hoffmann-La Roche Inc. Amino acid derivatives having antiviral activity
US5192764A (en) * 1991-05-30 1993-03-09 Research Foundation Of State Of N.Y. Pyrazinone n-oxide nucleosides and analogs thereof
US5169952A (en) * 1991-07-02 1992-12-08 Merck & Co., Inc. Stereoselective production of hydroxyamide compounds from chiral α-amino epoxides
JPH05208947A (ja) * 1991-08-16 1993-08-20 Merck & Co Inc Ｎ末端にポリエーテル置換基を有するｈｉｖプロテアーゼ抑制剤
WO1993008184A1 (en) * 1991-10-23 1993-04-29 Merck & Co., Inc. Hiv protease inhibitors
US5413999A (en) * 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
EP0541168B1 (en) * 1991-11-08 1998-03-11 Merck & Co. Inc. HIV protease inhibitors useful for the treatment of aids
CA2091151A1 (en) * 1992-03-13 1993-09-14 Kwan Y. Hui Retroviral protease inhibitors
DE69304393T2 (de) * 1992-04-01 1997-03-20 Searle & Co 2- und 3-Amino und Azidoderivate von 1,5-Iminozuckern als antivirale Arzneimittel
GB2270914A (en) 1992-09-14 1994-03-30 Merck & Co Inc HIV protease inhibitor compounds
US5430150A (en) * 1992-12-16 1995-07-04 American Cyanamid Company Retroviral protease inhibitors

Also Published As

Publication number Publication date
US5668132A (en) 1997-09-16
IL109503A0 (en) 1994-08-26
TW256830B (OSRAM) 1995-09-11
HU9503170D0 (en) 1996-01-29
US5413999A (en) 1995-05-09
BG100114A (bg) 1996-04-30
SK136395A3 (en) 1996-06-05
FI955315L (fi) 1995-11-06
WO1994026717A1 (en) 1994-11-24
BR9406576A (pt) 1996-01-30
FI955315A0 (fi) 1995-11-06
AU6669294A (en) 1994-12-12
EP0696277A1 (en) 1996-02-14
JPH08509980A (ja) 1996-10-22
CZ290095A3 (en) 1996-05-15
US5527799A (en) 1996-06-18
HUT73135A (en) 1996-06-28
CN1176250A (zh) 1998-03-18
CA2161334A1 (en) 1994-11-24
MX9403380A (es) 1995-01-31
CN1126469A (zh) 1996-07-10
NO954427L (no) 1996-01-08
NO954427D0 (no) 1995-11-06
FI955315A7 (fi) 1995-11-06
AU676563B2 (en) 1997-03-13
PL311635A1 (en) 1996-03-04
HRP940286A2 (en) 1996-08-31

Similar Documents

Publication Publication Date Title
HU9503170D0 (en) Hiv protease inhibitors useful for the treatment of aids
EP0434365A3 (en) Hiv protease inhibitors useful for the treatment of aids
EP0604182A3 (en) HIV protease inhibiting compounds.
AU4019289A (en) Hiv protease inhibitors useful for the treatment of aids
IL102428A0 (en) Inhibitors of hiv protease useful for the treatment of aids
PL313871A1 (en) Inhibitors of hiv protease
PL307858A1 (en) Sulphonamidic inhibitors of aspartilic hiv protease
FI935778A7 (fi) HIV-proteaasin inhibiittoreita, jotka ovat hyödyllisiä AIDSin hoitoa varten
PH31249A (en) Inhibitors of hiv protease.
IL108098A0 (en) Inhibitors of hiv protease useful for the treatment of aids
FI935777L (fi) AIDSin hoitamisessa käyttökelpoiset HIV-proteaasin inhibiittorit
PL314486A1 (en) Precursors of hiv protease inhibitors
IL105973A0 (en) Inhibitors of hiv protease useful for the treatment of aids
FI935779A7 (fi) HIV-proteaasin inhibiittoreita, jotka ovat hyödyllisiä AIDSin hoitoa varten
ZA925023B (en) Inhibitors of HIV protease useful for the treatment of AIDS
GB9515802D0 (en) Hiv protease inhibitors useful for the treatment of aids
AU2747397A (en) Hiv protease inhibitors useful for the treatment of aids
GB9508300D0 (en) HIV protease inhibtors for the treatment of aids
ZA939475B (en) Inhibitors of HIV protease useful for the treatment of Aids
GB9622443D0 (en) HIV protease inhibitors useful for the treatment of aids
GB9609663D0 (en) HIV Protease inhibitors useful for the treatment of aids
GB9613487D0 (en) HIV protease inhibitors useful for the treatment of aids
ZA9010125B (en) Hiv protease inhibitors useful for the treatment of aids
ZA928563B (en) HIV protease inhibitors useful for the treatment of AIDS.
ZA892627B (en) Hiv protease inhibitors useful for the treatment of aids